Neonatal derived mesenchymal stem cell mesotherapy in androgenetic alopecia: a retrospective observational study and review of literature
Background: Androgenetic alopecia has been a stressful condition for the patients and treating dermatologists alike. With the advent of stem cell therapy in various diseases, and lot of controversies and ethical issues related to it, mesenchymal stem cells MSC have passed the acid test successfully, though with many challenges. Since the stem cells in the hair follicle bulge and the dermal papilla play an important role in hair cycle and growth, introducing an external source of neonatal mesenchymal stem cells seems to be a possibility in the treatment of AGA. Aims: To know the benefits and safety of stem cell treatment in patients who underwent mesotherapy with neonatal MSC in order to establish the safety and efficacy in the treatment of AGA.
Methods: We collected data of 40 patients treated with mesoinjections of commercially prepared neonatal MSC, with AGA of grade 2 to 7. Before and after photographs, Patient (PtGA) and Physician (PGA) Global assessment scores were used to evaluate the treatment response.
Results: We found that 70% of the patients showed a mild response and 25% of them showed a moderate improvement in the hair growth and reduction in hair loss after 4 sittings of monthly duration. One subject showed an improvement of 72%. Patients had 6 month follow up. No major adverse events were observed.
Conclusions: Since this is an observational study, large randomized controlled studies, with longer follow ups is recommended to make MSC therapy a novel treatment option for AGA.Keywords: Mesenchymal stem cells, Mesotherapy, Androgenetic alopecia
Amoh Y, Li L, Katsuoka K, Hoffman RM. Embryonic development of hair follicle pluripotent stem (hfPS) cells. Med Mol Morphol. 2010 Jun;43(2):123-7.
Ito M, Kizawa K, Hamada K, Cotsarelis G. Hair follicle stem cells in the lower bulge form the secondary germ, a biochemically distinct but functionally equivalent progenitor cell population, at the termination of catagen. Differentiation. 2004;72(9-10):548-57.
Yoo BY, Shin YH, Yoon HH, Seo YK, Song KY, Park JK. Application of mesenchymal stem cells derived from bone marrow and umbilical cord in human hair multiplication. J Dermatol Sci. 2010 Nov;60(2):74-83.
Wang S, Qu X, Zhao RC. Clinical applications of mesenchymal stem cells. J Hematol Oncol. 2012;5:19.
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-7.
Parekkadan B, van Poll D, Suganuma K, Carter EA, Berthiaume F, Tilles AW, et al. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS One. 2007;2:e941.
Kwack MH, Sung YK, Chung EJ, Im SU, Ahn JS, Kim MK, et al. Dihydrotestosterone-inducible dickkopf 1 from balding dermal papilla cells causes apoptosis in follicular keratinocytes. J Invest Dermatol. 2008;128:262-9.
Dhurat R, Sukesh MS, Avhad G, Dandale A, Pal A, Pund P. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichol. 2013;5:6-11.
Hass R, Kasper C, Böhm S, Jacobs. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011;9:12.
Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003;102:3837-44.
Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449:557-63.
Guo M, Sun Z, Sun QY, Han Q, Yu CL, Wang DH, et al. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD. Biol Blood Marrow Transplant. 2009;15:930-7.